Successful Use of EPOCH-R in 2 Young Adult Patients With Burkitt Lymphoma and Acute Kidney Injury A Case ReportRoss, Savannah MD; Eisenman, Kristen MD; Maloney, Kelly W. MDJournal of Pediatric Hematology/Oncology: August 08, 2018 - Volume Publish Ahead of Print - Issue - p doi: 10.1097/MPH.0000000000001287 Clinical and Laboratory Observations: PDF Only Open PAP Abstract Author InformationAuthors Article MetricsMetrics Pediatric Burkitt lymphoma has historically been treated with intensive methotrexate-based chemotherapy, which improves patient survival while causing severe toxicities. Young patients typically have better outcomes with intensive therapies, while adults and immunocompromised patients have higher toxicities and worse outcomes. Newer treatment regimens, including etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab (EPOCH-R), show promise for these patients. However, few studies exist to demonstrate efficacy and improved toxicity profile with EPOCH-R. We present 2 cases: a 25-year-old male with Down syndrome and an 18-year-old male with Burkitt lymphoma and significant renal injury who were successfully treated with EPOCH-R with minimal toxicities. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ Department of Pediatric Hematology/Oncology/BMT, University of Colorado School of Medicine and Children’s Hospital Colorado, Aurora, CO The authors declare no conflict of interest. Reprints: Savannah Ross, MD, 13123 E., 16th Ave, B 115, Aurora, CO 80045 (e-mail: firstname.lastname@example.org). Received February 13, 2018 Accepted July 12, 2018 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.